Skip to main content
Log in

Relative lymphocyte count as a marker of progression of chronic kidney disease

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Background

Although low relative lymphocyte count (RLC) is associated with poor outcomes in patients with chronic kidney disease (CKD), the relationship between low RLC and progression of CKD is poorly defined. The aim of this study was to determine the association between low RLC and the progression of CKD.

Methods

Between January 2003 and December 2009, 288 CKD patients were analyzed. RLC was calculated as the ratio between lymphocyte and total white blood cell counts.

Results

The median RLC was 29.1 % [interquartile range (IQR) 24.1–34.1]. When the patients were compared according to a level below or above the median value for RLC, the rate of CKD progression to end-stage renal disease (ESRD) was greater in patients with low RLC count than in patients with high RLC (48 vs. 25 %, p < 0.001) during the median follow-up of 5.5 years (IQR 3.5–7.6). The variables found to be predictive of progression to the ESRD included younger age, smoking, diabetes, higher systolic blood pressure, no use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), lower hemoglobin and serum albumin levels, higher low-density lipoprotein cholesterol concentration, presence of proteinuria, and low RLC in the univariate Cox proportional hazards regression analysis. However, after adjustment, younger age, male, higher systolic blood pressure, no use of ACEIs or ARBs, lower hemoglobin and serum albumin concentrations, higher proteinuria, and lower RLC were significantly associated with progression to ESRD in multivariate analysis.

Conclusions

Low RLC is independently associated with increased rate of progression in patients with CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164(6):659–663

    Article  PubMed  Google Scholar 

  2. Elsayed EF, Tighiouart H, Griffith J et al (2007) Cardiovascular disease and subsequent kidney disease. Arch Intern Med 167(11):1130–1136

    Article  CAS  PubMed  Google Scholar 

  3. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–S266

    Google Scholar 

  4. Pecoits-Filho R, Heimbürger O, Bárány P et al (2003) Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41(6):1212–1218

    Article  PubMed  Google Scholar 

  5. Oberg BP, McMenamin E, Lucas FL et al (2004) Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65(3):1009–1016

    Article  PubMed  Google Scholar 

  6. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G, Cholesterol and Recurrent Events (CARE) Trial Investigators (2005) Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68(1):237–245

    Article  CAS  PubMed  Google Scholar 

  7. Stenvinkel P, Heimbürger O, Paultre F et al (1999) Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55(5):1899–1911

    Article  CAS  PubMed  Google Scholar 

  8. Kovesdy CP, Kalantar-Zadeh K (2009) Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol 29(1):3–14

    Article  CAS  PubMed  Google Scholar 

  9. Okyay GU, Inal S, Oneç K et al (2013) Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail 35(1):29–36

    Article  CAS  PubMed  Google Scholar 

  10. Kocyigit I, Eroglu E, Unal A et al (2013) Role of neutrophil/lymphocyte ratio in prediction of disease progression in patients with stage-4 chronic kidney disease. J Nephrol 26(2):358–365

    Article  CAS  PubMed  Google Scholar 

  11. Vannini FD, Antunes AA, Caramori JC, Martin LC, Barretti P (2009) Associations between nutritional markers and inflammation in hemodialysis patients. Int Urol Nephrol 41(4):1003–1009

    Article  CAS  PubMed  Google Scholar 

  12. Kovesdy CP, George SM, Anderson JE, Kalantar-Zadeh K (2009) Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease. Am J Clin Nutr 90(2):407–414

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470

    Article  CAS  PubMed  Google Scholar 

  14. Agarwal R, Light RP (2011) Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. Clin J Am Soc Nephrol 6(6):1393–1399

    Article  PubMed Central  PubMed  Google Scholar 

  15. Pifer TB, McCullough KP, Port FK et al (2002) Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 62(6):2238–2245

    Article  PubMed  Google Scholar 

  16. Reddan DN, Klassen PS, Szczech LA et al (2003) White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 18(6):1167–1173

    Article  CAS  PubMed  Google Scholar 

  17. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340(2):115–126

    Article  CAS  PubMed  Google Scholar 

  18. Verove C, Maisonneuve N, El Azouzi A, Boldron A, Azar R (2002) Effect of the correction of metabolic acidosis on nutritional status in elderly patients with chronic renal failure. J Ren Nutr 12(4):224–228

    Article  PubMed  Google Scholar 

  19. Lecker SH, Goldberg AL, Mitch WE (2006) Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17(7):1807–1819

    Article  CAS  PubMed  Google Scholar 

  20. Fried L, Solomon C, Shlipak M et al (2004) Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 15(12):3184–3191

    Article  PubMed  Google Scholar 

  21. Staples AO, Greenbaum LA, Smith JM et al (2010) Association between clinical risk factors and progression of chronic kidney disease in children. Clin J Am Soc Nephrol 5(12):2172–2179

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Friedman AN, Fadem SZ (2010) Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol 21(2):223–230

    Article  CAS  PubMed  Google Scholar 

  23. Caetano EP, Zatz R, Praxedes JN (1999) The clinical diagnosis of hypertensive nephrosclerosis—how reliable is it? Nephrol Dial Transplant 14(2):288–290

    Article  CAS  PubMed  Google Scholar 

  24. Takeichi N, Ba D, Kobayashi H (1981) Natural cytotoxic autoantibody against thymocytes in spontaneously hypertensive rats. Cell Immunol 60(1):181–190

    Article  CAS  PubMed  Google Scholar 

  25. Hoch NE, Guzik TJ, Chen W et al (2009) Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296(2):R208–R216

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Rodríguez-Iturbe B, Quiroz Y, Herrera-Acosta J, Johnson RJ, Pons HA (2002) The role of immune cells infiltrating the kidney in the pathogenesis of salt-sensitive hypertension. J Hypertens Suppl 20(30):S9–S14

    PubMed  Google Scholar 

  27. Eriksen BO, Ingebretsen OC (2006) The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 69(2):375–382

    Article  CAS  PubMed  Google Scholar 

  28. O’Hare AM, Choi AI, Bertenthal D, Bacchetti P et al (2007) Age affects outcomes in chronic kidney disease. J Am Soc Nephrol 18(10):2758–2765

    Article  PubMed  Google Scholar 

  29. Vlagopoulos PT, Tighiouart H, Weiner DE et al (2005) Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 16(11):3403–3410

    Article  PubMed  Google Scholar 

  30. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC (2004) Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66(2):753–760

    Article  PubMed  Google Scholar 

  31. Rossert J, Levin A, Roger SD et al (2006) Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47(5):738–750

    Article  CAS  PubMed  Google Scholar 

  32. Drüeke TB, Locatelli F, Clyne N et al (2006) CREATE investigators: normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355(20):2071–2084

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by the 2014 scientific promotion program funded by Jeju National University.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hyun Woo Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, S.M., Kim, H.W. Relative lymphocyte count as a marker of progression of chronic kidney disease. Int Urol Nephrol 46, 1395–1401 (2014). https://doi.org/10.1007/s11255-014-0687-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-014-0687-0

Keywords

Navigation